Stryker Corporation $SYK Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB trimmed its stake in Stryker Corporation (NYSE:SYK) by 1.1% during the second quarter, HoldingsChannel reports. The institutional investor owned 287,125 shares of the medical technology company’s stock after selling 3,128 shares during the period. Handelsbanken Fonder AB’s holdings in Stryker were worth $90,398,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SYK. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the 4th quarter valued at about $26,000. Sankala Group LLC acquired a new position in Stryker during the fourth quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new position in Stryker during the third quarter worth approximately $27,000. Atlas Capital Advisors Inc. purchased a new stake in Stryker in the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG purchased a new stake in Stryker in the fourth quarter valued at approximately $28,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE SYK opened at $345.05 on Tuesday. The stock has a fifty day moving average price of $321.03 and a 200 day moving average price of $333.81. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market cap of $132.35 billion, a PE ratio of 35.76, a P/E/G ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SYK. UBS Group began coverage on shares of Stryker in a research report on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price on the stock. Wells Fargo & Company reduced their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Barclays decreased their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Needham & Company LLC lowered their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Insider Transactions at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.